Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Regulatory issues in female sexual dysfunction

International Journal of Impotence Research volume 19, pages 526–529 (2007)Cite this article

Abstract

Editor's Note: Female sexual dysfunction (FSD) remains an enigmatic area to some, a controversial area to others and the subject of continued, intense debate in the literature. Questions remain regarding the legitimacy of FSD as a bona fide disease; the definition of FSD; the methods of diagnosis; and, the treatment of FSD. In this timely perspective, Jean Fourcroy, Consultant in Urology, Endocrinology and Regulatory Issues, discusses the controversies that continue to plague FSD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. The New York Times Science Section page 1 (April 10, 2007).

  2. Fourcroy J . Issues and priorities in the development of drug treatments for female sexual dysfunction. Int J Impot Res 1998; 10: S121–S123.

    Article  Google Scholar 

  3. Fourcroy JL . Female sexual function: potential for future pharmacotherapy. Invited lead article for DRUGS 2003; 63: 1445–1457.

    CAS  Google Scholar 

  4. Potts M, Short R . Ever Since Adam and Eve. Cambridge University Press: Cambridge UK, 1999.

  5. Alcantarra AG . A possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctions. J Ses Marital Ther 1999; 25: 125–129.

    Article  Google Scholar 

  6. Sato Y, Shibuya A, Adachi H, Kato R, Horita H, Tsukamoto T. Restoration of sexual behavior and dopaminergic neurotransmission by long term exogenous testosterone replacement in aged male rats. J Urol 1998; 150: 1572–1575.

    Article  Google Scholar 

  7. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classification. J Urol 2000; 163: 888–893.

    Article  CAS  Google Scholar 

  8. Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K et al. Definitions of women's sexual dysfunction reconsidered. J Psychosom Obstet Gynaecol 2003; 24: 221–227.

    Article  CAS  Google Scholar 

  9. Basson R, Shultz W, Bink YM, Brotte LA, Eschenbach DA, Laan E et al. Committee 16: women's sexual desire and arousal disorders and sexual pain. Proceedings of the 2nd international consultation on sexual function, 2004, pp 851–974.

  10. Guidance for Industry—female sexual dysfunction: clinical development of drug products for treatment. Draft Guidance, 2000, http://www.fda.gov/cder/guidance/3312dft.htm.

  11. FDA History, http://www.fda.gov/oc/history/default.htm. accessed May 1, 2007, http://www.fda.gov/womens/milesbro.html.

  12. Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544.

    Article  CAS  Google Scholar 

  13. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E et al. GSSAB Investigators' Group. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the global study of sexual attitudes and behaviors. Int J Impot Res 2005; 17: 39–57. Comment in: J Urol. 2005 Feb;173:545.

    Article  CAS  Google Scholar 

  14. Nicolosi A, Laumann EO, Glasser DB, Moreira Jr ED, Paik A, Gingell C, Global Study of Sexual Attitudes and Behaviors Investigators' Group. Sexual behavior and sexual dysfunctions after age 40 the global study of sexual attitudes and behaviors. Urology 2004; 64: 991–997.

    Article  Google Scholar 

  15. Rees PM, Fowler CJ, Maas CP . Sexual function in men and women with neurological disorders. Lancet 2007; 369: 512–525.

    Article  Google Scholar 

  16. Althof SE, Rosen RC, DeRogatis L, Corty E, Quirk F, Symonds T . Outcome measurement in female sexual dysfunction clinical trials: review and recommendations. J Sex Marital Ther 2005; 31: 153–166.

    Article  Google Scholar 

  17. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, February 2006. Available http://www.fda.gov/cder/guidance?5460dft.pdf.

  18. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'rien PJ et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005; 22: 499–511.

    Article  CAS  Google Scholar 

  19. Derogatis L R, Rosen R, Leiblum S, Burnett A, Heiman J. The female sexual distress scale (FSDS): Initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002; 28: 317–330.

    Article  Google Scholar 

  20. Quirk F, Heiman J, Rosen R et al. Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Womens Health Gend Based Med 2002; 11: 277–289.

    Article  Google Scholar 

  21. Rosen R, Brown C, Heiman J et al. The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191–208.

    Article  CAS  Google Scholar 

  22. Shames D, Monroe SE, Davis D, Soule L . Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder, formulating recommendations in an environment of evolving clinical science. Int J Impot Res 2007; 19: 30–36.

    Article  CAS  Google Scholar 

  23. Advisorymaterial for Intrinsa –testosterone transermal system –NDA 21769 November 3, 2004 document for Advisory Meeting) www.fda.gov/cder/ogd/0429clon.pdf;.

  24. American College of Obstetricians & Gynecologists (ACOG). Androgen replacement no panacea for women's libido. Press release, October 31, 2000.

  25. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006; 91: 3697–3710.

    Article  CAS  Google Scholar 

  26. Ferguson D . Hormones and FSD. Poster 49 Presentation International Society for the Study of Women's Sexual Health (ISSWSH) Orlando, Florida. February 23, 2007; Abstract in the Preceeding of the ISSWSH Annual Meeting page 16.

  27. Gerber JR, Johnson JV, Bunn JY, O'Brien SL . A longitudinal study of the effects of free testosterone and other psychosocial variables on sexual function during the natural traverse of menopause. Fertil Steril 2005; 83: 643–648.

    Article  CAS  Google Scholar 

  28. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H . Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405–413.

    Article  CAS  Google Scholar 

  29. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243–3253.

    Article  CAS  Google Scholar 

  30. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.

    Article  Google Scholar 

  31. Psaty BM, Burke SP . Protecting the health of the public—Institute of Medicine recommendations on drug safety. N Engl J Med 2006; 355: 1753–1755. Epub 2006 Oct 9.

    Article  CAS  Google Scholar 

  32. Psaty BM, Charo RA . FDA responds to institute of medicine drug safety recommendations—in part. JAMA 2007; 297: 1917–1920.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Consultant in Urology, U.SU.H.S./Walter Reed Army Hospital, Bethesda, MD, USA

    J L Fourcroy

Authors
  1. J L Fourcroy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J L Fourcroy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fourcroy, J. Regulatory issues in female sexual dysfunction. Int J Impot Res 19, 526–529 (2007). https://doi.org/10.1038/sj.ijir.3901595

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901595

Search

Advanced search

Quick links